MedTrace Logo

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT00487578 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.

Conditions

  • Post Traumatic Headache

Interventions

DRUG

naratriptan HCl

naratriptan 2.5mg tablet bid x 30 days OR matching placebo

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Clinvest

    collaborator OTHER

  • Cady, Roger, M.D.

    lead INDIV

Principal Investigators

  • Roger K Cady, MD · Clinvest

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487578 on ClinicalTrials.gov